You're staring at a textbook diagram of a cell. Day to day, the nucleus is labeled. Also, the mitochondria. The Golgi apparatus. And then there's this little note: "MHC class I — cell surface." "MHC class II — cell surface.
That's it. That's the whole explanation The details matter here..
But if you've ever actually worked with these molecules — tried to stain them, isolate them, or figure out why your flow cytometry data looks weird — you know the real answer is messier. And way more interesting Small thing, real impact. Worth knowing..
What Are MHC Molecules Anyway
MHC stands for major histocompatibility complex. Plus, fancy name. The molecules themselves are glycoproteins — proteins with sugar chains attached — that sit in the cell membrane and present peptide fragments to T cells. Think of them as the cell's way of saying "here's what I've been up to lately" to the immune system.
Two main classes. Class I molecules (HLA-A, -B, -C in humans) are on virtually every nucleated cell. Class II molecules (HLA-DP, -DQ, -DR) are more selective — mostly on professional antigen-presenting cells like dendritic cells, macrophages, and B cells Worth knowing..
But "cell surface" is the lazy answer. The real story starts way before they get there Small thing, real impact..
Where They're Actually Located — The Full Journey
Born in the ER
Every MHC molecule starts life in the endoplasmic reticulum. This is non-negotiable. The heavy chain (for class I) or alpha and beta chains (for class II) are synthesized by ribosomes on the rough ER, then translocated into the ER lumen where they fold.
Here's what most textbooks skip: class I heavy chains don't fold properly on their own. Now, they need a chaperone called calnexin first. Then they need beta-2 microglobulin (β2m) — a light chain that isn't even encoded in the MHC locus. No β2m, no stable class I molecule. The complex just falls apart and gets degraded Took long enough..
Class II is different. The alpha and beta chains pair up in the ER with a third protein called the invariant chain (Ii). Consider this: the invariant chain blocks the peptide-binding groove. On purpose. Because if class II bound peptides in the ER, it would grab ER-resident peptides — useless for immune surveillance.
The Golgi Pit Stop
From the ER, properly assembled complexes move to the Golgi apparatus. Here's the thing — this is where glycosylation gets finished. The sugar trees on MHC molecules aren't decoration — they affect folding, stability, and even which peptides can bind.
For class I, the journey is relatively direct: ER → Golgi → plasma membrane. But class II takes a detour Not complicated — just consistent..
The Endosomal Detour (Class II Only)
Remember the invariant chain? But it has a sorting signal in its cytoplasmic tail that routes the whole complex away from the default secretory pathway. Instead of going straight to the surface, class II-invariant chain complexes get packaged into vesicles that fuse with late endosomes and lysosomes Which is the point..
Counterintuitive, but true Not complicated — just consistent..
Basically where the magic happens. Dead cell debris. Then HLA-DM (a non-classical MHC molecule) kicks CLIP out and helps load peptides derived from endocytosed proteins. On top of that, bacteria. Viruses. Worth adding: the invariant chain gets chewed up by proteases — mostly cathepsins — leaving just a small fragment called CLIP still stuck in the peptide-binding groove. Whatever the cell has swallowed recently.
Only then does the peptide-loaded class II molecule head to the surface.
The Plasma Membrane — But Not Randomly
So yes, mature MHC molecules end up at the plasma membrane. But they're not scattered like sprinkles on a donut.
Lipid rafts. Both class I and class II molecules partition into cholesterol-rich membrane microdomains. This matters because T cell receptors and co-receptors (CD8 for class I, CD4 for class II) also concentrate there. The immune synapse — that tight junction between a T cell and its target — forms in these rafts. MHC molecules are pre-positioned for the conversation Nothing fancy..
Polarized distribution. In polarized cells — neurons, intestinal epithelial cells, activated T cells — MHC molecules aren't evenly distributed. Class I tends toward the basolateral surface in epithelia. In neurons, it's dendritic. This isn't random; it shapes which T cells can "see" the antigen Worth knowing..
Internal pools. Here's the kicker: at any given moment, a significant fraction of MHC molecules aren't on the surface. They're cycling. Class I molecules internalize via clathrin-mediated endocytosis, travel through early endosomes, and either recycle back or get degraded. Class II does the same but faster. The surface pool is in constant flux.
Why This Matters More Than You Think
For Pathogen Evasion
Viruses know this geography better than most textbooks. Adenovirus? Also, reroutes class I to lysosomes for degradation. HIV Nef protein? They retain class I in the ER. That said, herpesviruses? Blocks TAP transporter so no peptides reach the ER. Now, cytomegalovirus? Has multiple proteins targeting different steps — ER retention, dislocation to cytosol for proteasomal destruction, you name it Surprisingly effective..
They don't just "downregulate MHC." They surgically disrupt specific trafficking steps. Knowing where the bottleneck is lets you understand how the virus wins Small thing, real impact..
For Transplantation
HLA matching is basically MHC matching. So dendritic cells from the donor (passenger leukocytes) migrate to recipient lymph nodes and directly stimulate alloreactive T cells. But the location matters too. Endothelial cells lining blood vessels express both class I and class II — and they're the first thing recipient T cells see after transplant. The cellular address of MHC determines the rejection kinetics.
For Cancer Immunotherapy
Tumor cells often lose class I — but not always completely. CAR-T cells? Consider this: others lose β2m. And the tumor microenvironment? Full of cytokines that should upregulate MHC (IFN-γ) but tumors develop resistance. Some downregulate TAP. Think about it: checkpoint inhibitors work better when MHC is present and functional. Others keep class I but lose specific alleles. They don't need MHC — but bispecific antibodies and TCR-based therapies absolutely do And that's really what it comes down to..
How It Works — The Trafficking Machinery
Signal Sequences and Sorting Signals
Every MHC molecule has a cytoplasmic tail. Which means short. In real terms, 30-50 amino acids. But packed with information Easy to understand, harder to ignore..
Class I tails have tyrosine-based sorting motifs (YXXΦ) that bind AP-2 adaptor complexes for clathrin-mediated endocytosis. They also have dileucine motifs. Mutate these, and the molecule stays on the surface longer — but internalization isn't just degradation. It's also a chance to reload peptides in endosomes. Yes, class I can cross-present. The recycling pathway matters And that's really what it comes down to..
Class II tails are longer. The invariant chain does the heavy lifting early, but once it's gone, the class II tail itself has sorting signals — again, dileucine and tyrosine motifs — that control endosomal targeting and recycling.
The Peptide Editing Stations
ER quality control: Calnexin, calreticulin, ERp57, tapasin. Tapasin bridges MHC class I to TAP (transporter associated with antigen processing). This isn't just folding — it's peptide editing. Tapasin rejects low-affinity peptides. The result? Surface class I molecules are enriched for high-affinity, stable peptides.
Endosomal editing: HLA-DM for class II. HLA-DO (in humans) regulates DM. The pH drops from early to late endosomes, and proteases generate the peptide
repertoire. These editing steps aren’t just about quality—they dictate which peptides get displayed, shaping the immune response’s specificity Took long enough..
The Viral Sabotage Playbook
Viruses exploit every node. Herpesviruses encode proteins like US6 (HCMV) that block TAP, halting peptide loading. HIV’s Nef downregulates MHC class I by redirecting it to lysosomes. Cytomegalovirus’s US2 and US11 target β2m, destabilizing the MHC class I complex. Each tactic is a precision strike: US6 cripples the ER’s peptide factory, while US11 hijacks proteasomal degradation pathways to generate “garbage” peptides that poison the cell. The bottleneck varies, but the outcome is the same: a stealthy presentation profile That alone is useful..
Transplantation: The Double-Edged Surface
In transplants, endothelial cells’ dual MHC class I/II expression creates a paradox. Class I activates CD8+ T cells, while class II engages CD4+ helpers—both primed to attack foreign tissue. Donor dendritic cells exacerbate this by migrating to lymph nodes, where they present alloantigens alongside recipient MHC, accelerating T-cell activation. The location of MHC expression isn’t incidental; it’s a battlefield. A mismatched kidney’s endothelial cells might be the first domino, but passenger leukocytes ensure the collapse spreads Small thing, real impact..
Cancer: A Game of Adaptation
Tumors evolve to evade MHC. Loss of β2m or TAP renders them invisible to CD8+ T cells, but incomplete downregulation leaves pockets of vulnerability. Checkpoint inhibitors like anti-PD-1 require functional MHC to reactivate T cells—no MHC, no response. Meanwhile, tumors secrete TGF-β or IDO to suppress dendritic cells, further dampening antigen presentation. Yet some immunotherapies bypass MHC: CAR-T cells recognize tumor surface antigens directly, while TCR-engineered T cells target MHC-bound neoantigens. The lesson? MHC is not a monolith; its absence or modification demands tailored strategies Worth keeping that in mind. Took long enough..
Conclusion: Precision in the Peptide Display
MHC trafficking is a choreographed dance of assembly, editing, and transport. Viruses weaponize this system with surgical precision, while immunotherapies and transplants hinge on decoding its geography. Whether it’s a tumor evading detection or a transplant triggering rejection, the bottleneck in MHC presentation dictates the outcome. Understanding these mechanisms isn’t just academic—it’s a roadmap for designing therapies that turn the immune system’s blind spots into strengths. In the end, MHC isn’t just a marker; it’s a battleground where survival hinges on control over the peptide narrative Still holds up..
